Robert Smith, MD
Obstetrics & Gynecology · New Port Richey, FLNPI 1457370884
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,307 of the $5,252 with a category attached, or 82.0%. 35 manufacturers reported payments, led by Intuitive Surgical at 24.2% of the total. Reporting peaked in 2023 at $1,635 and has fallen 76.8% since, to $380 in 2025.
Across 215 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- AbbVie$924
- Novo Nordisk$407
- Astellas Pharma US Inc$368
- Exeltis, USA Inc.$272
- Agile Therapeutics, Inc.$230
- plus $2K from 29 others
Across 227 payments — averaging $3061.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$311K
- Bayer$129K
- Mylan Inc.$119K
- AbbVie$87K
- Mylan Technologies Inc.$27K
- Teva Pharmaceuticals USA, Inc.$23K
What the payments were for
- Travel & lodging$83916%
- Food & beverage$4,30782%
- Education$1062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $1,269 |
| AbbVie(2 entities) | 55 | $924 |
| Novo Nordisk | 22 | $407 |
| Astellas Pharma US Inc | 15 | $368 |
| Exeltis, USA Inc. | 4 | $272 |
| Agile Therapeutics, Inc. | 13 | $230 |
| Myovant Sciences Inc. | 6 | $149 |
| Bayer | 7 | $135 |
| Johnson & Johnson | 7 | $134 |
| Pfizer | 7 | $123 |
| Lilly USA, LLC | 8 | $121 |
| Mylan Pharmaceuticals Inc. | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Shield Therapeutics Inc | 5 | $88 |
| Millicent US Inc | 4 | $88 |
| Medline Industries LP | 1 | $81 |
| Vifor Pharma, Inc. | 3 | $75 |
| Coopersurgical, Inc. | 4 | $73 |
| GSK | 4 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Evofem Biosciences, Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $43 |
| Therapeuticsmd, Inc. | 3 | $39 |
| Scynexis, Inc. | 2 | $31 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Merck | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
| Avion Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$820
- Slynd$215
How this compares
$5,252 in reported general payments places this provider in the 85th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 32 | $13,783 |
| Estradiol | 157 | $3,584 |
| Medroxyprogesterone Acetate | 95 | $1,325 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 21 | $1,033 |
| Metronidazole | 25 | $619 |
| ProgesteroneProgesterone, Micronized | 20 | $616 |
| Terconazole | 19 | $507 |
| Acyclovir | 17 | $498 |
| Fluconazole | 33 | $452 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $422 |
| SprintecNorgestimate-Ethinyl Estradiol | 16 | $214 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $200 |
| Clindamycin Hcl | 15 | $103 |
| Ibuprofen | 22 | $85 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $123 | $13,78332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,438 obstetrics & gynecology providers in Florida.
Other obstetrics & gynecology in New Port Richey
- Steven McCarusCelebration$2.3M
- Elliot CazesTampa$725K
- Charles BloomWinter Park$652K
- Jay CohenPlantation$556K
- Omar ZwainWinter Park$531K
- Keith AquaWellington$473K
- Jeffrey KotzenPalm Beach Gardens$413K
- Glenn BankertCrestview$388K
- Erica StockwellCelebration$321K
- Scott JordanFort Lauderdale$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.